Piper Sandler
RatingNeutral unchanged
Price target$9 → $6 −33.3% · −$3
Price at note$4.43 (Oct 23 close) +35.4% upside (+$1.57) to the $6 target
Third-party analyst actions
Analyst moves
Upgrades, downgrades, new coverage and price-target changes from Wall Street firms on the stocks we cover. What each firm published, laid out plainly. These are third-party actions, not our views.
Try one
23 moves · this week
ⓘ Rating colors
- Strong BuyConviction Buy, Top Pick, Top Pick Buy
- BuyLong Term Buy, Speculative Buy, Outright Buy
- OutperformOverweight, Accumulate, Moderate Buy, Positive
- HoldNeutral, Equal Weight, Market Perform, Sector Perform
- UnderperformUnderweight, Reduce, Moderate Sell, Negative
- Sell
- Strong Sell
- OtherRatings we can't place on the scale
Each firm's own wording is placed on one seven-step scale so ratings compare at a glance. ▲ / ▼ between two ratings marks an upgrade or a downgrade. The colours describe what the firm said; they are not our view.
Friday · Oct 23, 2026
ELVElevance Health$439.95TD Cowen
RatingBuy unchanged
Price target$465 → $495 +6.5% · +$30
Price at note$439.95 (Oct 23 close) +12.5% upside (+$55.05) to the $495 target
Evercore ISI Group
RatingOutperform unchanged
Price target$47 → $40 −14.9% · −$7
Price at note$27.52 (Oct 23 close) +45.3% upside (+$12.48) to the $40 target
Mizuho
RatingOutperform unchanged
Price target$43 → $37 −14.0% · −$6
Price at note$27.52 (Oct 23 close) +34.4% upside (+$9.48) to the $37 target
Thursday · Oct 22, 2026
ZSZscaler, Inc.$212.53Freedom Broker
RatingBuy unchanged
Price target$230 → $270 +17.4% · +$40
Price at note$212.53 (Oct 19 close, before the note) +27.0% upside (+$57.47) to the $270 target
ELVElevance Health$439.95UBS
RatingBuy unchanged
Price target$460 → $523 +13.7% · +$63
Price at note$445.28 (Oct 22 close) +17.5% upside (+$77.72) to the $523 target
ELVElevance Health$439.95Guggenheim
RatingBuy unchanged
Price target$460 → $485 +5.4% · +$25
Price at note$445.28 (Oct 22 close) +8.9% upside (+$39.72) to the $485 target
ELVElevance Health$439.95Morgan Stanley
RatingEqual-Weight unchanged
Price target$404 → $449 +11.1% · +$45
Price at note$445.28 (Oct 22 close) +0.8% upside (+$3.72) to the $449 target
ELVElevance Health$439.95RBC Capital
RatingSector Perform unchanged
Price target$424 → $455 +7.3% · +$31
Price at note$445.28 (Oct 22 close) +2.2% upside (+$9.72) to the $455 target
ELVElevance Health$439.95Barclays
RatingOverweight unchanged
Price target$469 → $472 +0.6% · +$3
Price at note$445.28 (Oct 22 close) +6.0% upside (+$26.72) to the $472 target
ELVElevance Health$439.95Baird
RatingNeutral unchanged
Price target$393 → $406 +3.3% · +$13
Price at note$445.28 (Oct 22 close) −8.8% downside (−$39.28) to the $406 target
CLFCleveland-Cliffs$13.90B. Riley Securities
RatingBuy unchanged
Price target$15 → $18 +20.0% · +$3
Price at note$13.05 (Oct 22 close) +37.9% upside (+$4.95) to the $18 target
CLFCleveland-Cliffs$13.90Barclays
RatingUnderweight unchanged
Price target$11 → $12 +9.1% · +$1
Price at note$13.05 (Oct 22 close) −8.0% downside (−$1.05) to the $12 target
CLFCleveland-Cliffs$13.90JP Morgan
RatingNeutral unchanged
Price target$12 → $13 +8.3% · +$1
Price at note$13.05 (Oct 22 close) −0.4% downside (−$0.05) to the $13 target
Wednesday · Oct 21, 2026
Morgan Stanley
RatingOverweight unchanged
Price target$141 → $132 −6.4% · −$9
Price at note$91.64 (Oct 21 close) +44.0% upside (+$40.36) to the $132 target
Wells Fargo
RatingOverweight unchanged
Price target$45 → $40 −11.1% · −$5
Price at note$28.12 (Oct 21 close) +42.2% upside (+$11.88) to the $40 target
TD Cowen
RatingBuy▼Hold
Price target$44 → $32 −27.3% · −$12
Price at note$28.12 (Oct 21 close) +13.8% upside (+$3.88) to the $32 target
Tuesday · Oct 20, 2026
CLFCleveland-Cliffs$13.90Morgan Stanley
RatingEqual-Weight unchanged
Price target$12.50 → $14 +12.0% · +$1.50
Price at note$13.65 (Oct 20 close) +2.6% upside (+$0.35) to the $14 target
CLFCleveland-Cliffs$13.90Wells Fargo
RatingOverweight unchanged
Price target$14 → $17 +21.4% · +$3
Price at note$13.65 (Oct 20 close) +24.5% upside (+$3.35) to the $17 target
Monday · Oct 19, 2026
VEEVVeeva Systems$323.04Barclays
RatingOverweight unchanged
Price target$315 → $360 +14.3% · +$45
Price at note$316.80 (Oct 19 close) +13.6% upside (+$43.20) to the $360 target
BMO Capital
RatingMarket Perform unchanged
Price target$105 → $97 −7.6% · −$8
Price at note$89.58 (Oct 19 close) +8.3% upside (+$7.42) to the $97 target
Citigroup
RatingBuy unchanged
Price target$45 → $43 −4.4% · −$2
Price at note$29.85 (Oct 19 close) +44.1% upside (+$13.15) to the $43 target
CLFCleveland-Cliffs$13.90Barclays
RatingUnderweight unchanged
Price target$10 → $11 +10.0% · +$1
Price at note$14.10 (Oct 19 close) −22.0% downside (−$3.10) to the $11 target
Source: Yahoo Finance analyst upgrades and downgrades (firm, rating, price target), refreshed after each US market close for the stocks Coteau covers. Yahoo doesn't name the individual analyst. "Price at note" is that day's closing price from our daily price history (the prior close when the note came before the open); the upside or downside is the distance from it to the new target. Details opens the matching news story when we have one, otherwise the stock's Yahoo Finance analysis page. Ratings and targets belong to the firms named; Coteau doesn't rate stocks, set targets or give advice. Not investment advice · Important disclosures
Get the market emails
Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdaysIndexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.
Check your inbox to confirm
We sent a link to . Tap it to start your emails. Nothing is sent until you confirm.
Not there in a minute? Check spam, or .
Dev mode No email provider here, so the confirm link is shown: Open confirm link
coteau
Free to use. No card, no ads, no auto-renew.
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Coteau 0.9 · Oct 21, 2026